ZLNA ZELLUNA ASA

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET.

Attendance by registration only. 

The format will be a panel discussion and open questions and answers (Q&A).

The panel will include:

Dr. Namir Hassan, CEO, Zelluna ASA, Moderator

Prof. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer; former founder of two public TCR based companies including Immunocore. Zelluna ASA Board Member.

Prof Fiona Thistlethwaite, Medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, UK

Details of the event are as follows:

Date: Wednesday 17 September 2025.

Time: 11:30 – 13:00 CET, Lunch served.

Venue: Meeting Room 4, Hotel Continental, Stortingsgata 24/26, Oslo.

Format: Panel discussion and open Q&A 12:00 – 13:00 CET.

Attendance is by registration only and spaces are limited.

Please confirm your registration by Monday 15 September 2025 by email to:

Hans Vassgård Eid, CFO, Zelluna ASA on:

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

Email:

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email:

Phone:

About Zelluna ASA

Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of “off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used “off the shelf” to overcome scaling limitations of current cell therapies. The lead program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products.

For more information, please visit



 



EN
10/09/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Notice of extraordinary general meeting on 25 November 20...

Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering.  The Company's board of directors (the "Board") hereby calls for an extraordinary general meeting on 25 November 2025 at 09:00 CET (the "EGM") to resolve upon proposals by the Board to issue the new shares in tranche 2 of the private placement and to authorize the Board to issue new shares in a potential subsequent repair offer...

November 4, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Disclosure of large shareholding

Zelluna ASA: Disclosure of large shareholding In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold following the share capital increase in Zelluna through the private placement on November 3rd 2025. Previous shareholding : 10,79% New shareholding : 9,01% Total number of shares held: 2,207,034 The reduction in ownership is due to dilution as result of the private placement. Inven2 has not sold any shares. This notification is submitted pursu...

November 4, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Disclosure of large shareholding

Zelluna ASA: Disclosure of large shareholding Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the "Retail Offering").  Radforsk Investeringsstiftelse ("Radforsk") holds 2,469,693 shares in the Company, representing 12.07...

November 4, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA – Ex. date

Zelluna ASA – Ex. date The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025. This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.  

November 4, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA – Key information relating to subsequent offering

Zelluna ASA – Key information relating to subsequent offering Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the "PrimaryBid Offering"), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private Placement and the PrimaryBid Offering (the "Subsequent Offering"). The Subsequ...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch